Clinical study
Side effects of systemic cyclosporine in patients not undergoing transplantation

https://doi.org/10.1016/0002-9343(84)90356-5Get rights and content

Abstract

Twenty-six patients with ocular inflammatory disorders of presumed autoimmune origin were treated with oral cyclosporine. Cyclosporine is a potent T cell regulatory agent that has been utilized extensively in organ transplantation. In general, the patients in this study did not have chronic debilitating illnesses that are observed in organ transplant recipients, did not receive corticosterolds in addition to cyclosporine, and did not undergo any surgical procedure during their treatment. This study describes the observed adverse reactions in this group of patients not undergoing transplantation. The reported side effects of cyclosporine in organ transplant recipients have included nephrotoxicity, hepatotoxicity, infections, lymphoma, hirsutism, gingivitis, and central nervous system toxicity. Side effects were observed that were similar to those in previous reports, but the severity of the nephrotoxicity and hepatotoxicity appeared to be less. Nephrotoxicity occurred in eight patients and hepatotoxicity occurred in one patient. No lymphomas were seen. Hypertension and anemia each were observed in six patients. In addition, previously unreported effects of hyperuricemia, elevated sedimentation rate, and hidradenits were observed. However, the overall severity of the side effects did not seriously affect the usage of cyclosporine in the patients in this study. Cyclosporine may be useful in the treatment of other autoimmune diseases.

References (19)

There are more references available in the full text version of this article.

Cited by (264)

  • Cis-trans isomerization in cyclosporin C dissolved in acetonitrile

    2023, Biochemical and Biophysical Research Communications
  • Ocular delivery of cyclosporine A using dissolvable microneedle contact lens

    2022, Journal of Drug Delivery Science and Technology
  • Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?

    2018, Clinical Therapeutics
    Citation Excerpt :

    Healthy male volunteers aged ≥18 years were recruited by public advertisements in the surrounding community. In addition to information on possible serious adverse events while on long-term CsA treatment, participants were informed about 4 potential, subjectively perceivable, and highly frequent CsA-related adverse events that can occur with short-term CsA administration according to Ellis et al,31 Gupta et al,32 Palestine et al,33 and Wendt et al34 (ie, heat sensation in the hands and head, tingling sensation in the hands, fatigue/faster exhaustion, and nausea/discomfort in the intestine and stomach). All participants underwent in-depth physical and psychological assessments, including self-reported questionnaires and an interview about their medical history.

  • Drug-associated hidradenitis suppurativa: A systematic review of case reports

    2018, Journal of the American Academy of Dermatology
  • Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

    2017, European Journal of Pharmaceutics and Biopharmaceutics
    Citation Excerpt :

    Initially, CsA was administered orally for the treatment of ophthalmic diseases. Although CsA was able to reach therapeutic levels in different ocular tissues [9], the non-ocular administration led to occurrence of systemic adverse events such as nephrotoxicity, hypertension, anemia, paresthesia and hyperesthesia [10]. Therefore, local (ocular) administration of CsA-loaded products became the preferred method of delivery for treatment of ophthalmic pathologies.

  • Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier

    2015, Toxicology in Vitro
    Citation Excerpt :

    As PK evaluation is necessary to describe the systemic exposure and its relationship to observed (adverse) effects, PK data enhance the understanding of mechanisms of action and/or toxicity induced by xenobiotics and moreover help to assess the risk and safety in humans (ICH S3A Guideline; OECD Test Guideline No. 417). The cyclic peptide cyclosporine A (CsA), which is a widely used immunosuppressive compound, was chosen as a cross-organ test compound in the “Predict-IV” project as it has been shown to induce hepatotoxicity (Atkinson et al., 1983; Klintmalm et al., 1981), nephrotoxicity (Bennett and Pulliam, 1983; Klintmalm et al., 1985; Palestine et al., 1984) and also neurotoxicity (Calne et al., 1979; Gijtenbeek et al., 1999). As the therapeutic index of CsA is narrow, therapy requires drug monitoring to avoid toxicity.

View all citing articles on Scopus
1

From the Clinical Ophthalmic Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, Maryland.

View full text